nope, R & D is an investment and sit on the balance sheet, so your statement is totally incorrect
Um, not in the context of what we are discussing here.
Without getting bogged down in a long technical accounting lecture that I am sure most here have no interest in (read up on IAS 38 Intangible assets if you are genuinely interested), the fundamental key element to remember is that:
A company can only recognised an asset from in-house R&D when it is probable that economic benefit will arrise from it (secondary requirement that costs can be reliably measured is easy to meet and should never be a stumbling block to asset recognition).
That means that if your R&D takes 10 years to complete, you cannot recognise a R&D asset in any of the first 9 years of development.
Instead you only recognise the expenses incurred on the R&D project in those first 9 years and charge those to your P&L, thereby reducing your annual profits for the first 9 years.
The other major problem with your statement is that balance sheet assets have little direct impact on your profits (P&L) other than to reduce it through annual amortisation costs (assets with infinite useful life are so rare as to be practically non-existent in real life).
Thus having a massive value investment asset sitting on your balance sheet is not a good thing in itself even when you can recognise it! It’s the income that such assets generates that is key.
When managers make investment decisions, it’s expected sales that they care most about, and those expected income returns are offset against both the duration of the R&D project, as well as the costs of that R&D project overall to determine if that project is worthwhile to pursue.
Because of those characteristics, private R&D overwhelmingly focuses on the highest population market segment.
If, for example out of a standardised population of 100, only 1 person is affected by the issue the R&D project in question, unless that 1% is the top 1% in terms of income, that project is just never going to be green lighted in the private sector. Risk factor is also a massive consideration, with possibility of failure also playing a critical part in whether a project is approved.
While that is ‘efficient’ at the micro level in terms of waste management; it is also incredibly slow to push out the boundaries of scientific possibilities, since that boundary tend to only get advanced at the margins.
Private R&D can also be incredibly inefficient at the macro level when you can have several; dozens or even hundreds of companies all investing to develop the same technologies. Indeed, one of the most powerful trump card arguments that can get a private R&D project funded, almost irrespective of its inherent merits, is if it is known a key rival and competitor is researching it, or has such a product already on market.